Roche Holding Stock Forecast for 2022 - 2025 - 2030

Updated on 05/25/2022

Stock Rating
3 / 10
Price Target
CHF391.00
Consensus
Outperform
Upside
12.94%
Analysts
20
Stock Rating
3
Upside
12.94%
Analysts
20
Price Target
CHF391.00

Roche Holding's stock is projected to advance by 12.94% from the previous closing price if it reaches the average target of CHF391.00 by the year's end, as twenty reputable analysts recently projected. This potential upside is calculated on a high-end estimate of CHF475.80 and a low-end estimate of CHF330.00. If you're looking for information on Roche Holding stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

CHF391.00

12.94% Upside

Outperform
Outperform

Roche Holding Fair Value Forecast for 2022 - 2025 - 2030

Roche Holding's Fair Value has increased by 9.21% in the last three years, going from CHF288.79 to CHF315.38. In the next year, analysts expect Fair Value to reach an unimpressive CHF334.84 – an increase of 6.17%. For the next nine years, the forecast is for Fair Value to grow by 51.11%.

2022 Fair Value Forecast
CHF334.84
2023 Fair Value Forecast
CHF350.82
2024 Fair Value Forecast
CHF366.77
2025 Fair Value Forecast
CHF384.75
2026 Fair Value Forecast
CHF402.15
2027 Fair Value Forecast
CHF420.05
2028 Fair Value Forecast
CHF438.62
2029 Fair Value Forecast
CHF457.36
2030 Fair Value Forecast
CHF476.55
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
LLY Stock Forecast Eli Lilly and Outperform 5
$305.96 $281.95 4.92% 12
ABBV Stock Forecast AbbVie Outperform 6
$149.11 $152.52 12.5% 19
AVGO Stock Forecast Broadcom Outperform 7
$524.20 $687.47 33.54% 25
AZN Stock Forecast AstraZeneca PLC Outperform 3
£104.94 £136.08 39% 13
ABT Stock Forecast Abbott Laboratories Outperform 7
$113.77 $141.24 23.06% 19

Roche Holding Revenue Forecast for 2022 - 2025 - 2030

Roche Holding's Revenue has increased by 10.68% in the last three years, going from CHF59.50B to CHF65.85B. In the next year, analysts expect Revenue to reach an unimpressive CHF70.39B – an increase of 6.89%. For the next nine years, the forecast is for Revenue to grow by 74.21%.

2022 Rev Forecast
CHF70.39B
2023 Rev Forecast
CHF75.19B
2024 Rev Forecast
CHF80.50B
2025 Rev Forecast
CHF85.71B
2026 Rev Forecast
CHF91.16B
2027 Rev Forecast
CHF96.83B
2028 Rev Forecast
CHF102.60B
2029 Rev Forecast
CHF108.57B
2030 Rev Forecast
CHF114.72B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
DHR Stock Forecast Danaher Outperform 5
$252.00 $339.17 32.94% 7
BMY Stock Forecast Bristol-Myers Squibb Outperform 8
$77.13 $76.69 1.13% 16
AMGN Stock Forecast Amgen Hold 6
$251.89 $246.46 -0.75% 13

Roche Holding Dividend per Share Forecast for 2022 - 2025 - 2030

In the past three years, Roche Holding's DPS has slightly grown, increasing from CHF8.70 to CHF9.30 – a growth of 6.9%. The next year looks mildly promising for Roche Holding, with analysts predicting DPS of CHF9.50 – an increase of 2.19%. Over the next nine years, experts anticipate that ROG's DPS will grow at a rate of 18.84%.

2022 DPS Forecast
CHF9.50
2023 DPS Forecast
CHF9.68
2024 DPS Forecast
CHF9.87
2025 DPS Forecast
CHF10.06
2026 DPS Forecast
CHF10.26
2027 DPS Forecast
CHF10.45
2028 DPS Forecast
CHF10.65
2029 DPS Forecast
CHF10.85
2030 DPS Forecast
CHF11.05
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MMM Stock Forecast 3M Hold 5
$145.75 $188.41 9.98% 17
GE Stock Forecast General Electric Outperform 2
$74.52 $121.44 43.59% 13
BDX Stock Forecast Becton, Dickinson and Outperform 5
$257.45 $270.20 10.7% 3

Roche Holding Free Cash Flow Forecast for 2022 - 2025 - 2030

In the past three years, Roche Holding's Free Cash Flow has seen a tremendous increase, going from CHF15.94B to CHF17.45B – an increase of 9.49%. Next year, analysts are expecting Free Cash Flow to reach CHF20.65B – an increase of 18.32%. Over the next nine years, the forecast is for Free Cash Flow to grow by 226.07%.

2022 FCF Forecast
CHF20.65B
2023 FCF Forecast
CHF24.42B
2024 FCF Forecast
CHF28.06B
2025 FCF Forecast
CHF32.17B
2026 FCF Forecast
CHF36.59B
2027 FCF Forecast
CHF41.21B
2028 FCF Forecast
CHF46.16B
2029 FCF Forecast
CHF51.39B
2030 FCF Forecast
CHF56.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14
BSX Stock Forecast Boston Scientific Outperform 4
$40.15 $49.85 24.53% 23
4519 Stock Forecast Chugai Pharmaceutical Hold 3
¥3.79k ¥0.00 18.73% 0

Roche Holding Net Income Forecast for 2022 - 2025 - 2030

In the last three years, Roche Holding's Net Income has grown by 32.67%, from CHF10.50B to CHF13.93B. For the next year, analysts are expecting Net Income to reach a reasonable CHF15.34B – an increase of 10.13%. Over the next nine years, experts predict that Net Income will grow by 72.54%.

2022 NI Forecast
CHF15.34B
2023 NI Forecast
CHF16.23B
2024 NI Forecast
CHF17.17B
2025 NI Forecast
CHF18.32B
2026 NI Forecast
CHF19.37B
2027 NI Forecast
CHF20.48B
2028 NI Forecast
CHF21.65B
2029 NI Forecast
CHF22.82B
2030 NI Forecast
CHF24.03B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 2
¥2.83k ¥0.00 36.07% 0
ALC Stock Forecast Alcon Outperform 0
CHF79.00 CHF0.00 15.3% 14
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3

Roche Holding EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Roche Holding's EBITDA has grown by 7.83%, rising from CHF22.51B to CHF24.27B. For next year, analysts predict earnings per share of CHF25.55B, which would mean an increase of 5.3%. Over the next nine years, experts predict that Roche Holding's EBITDA will grow at a rate of 39.12%.

2022 EBITDA Forecast
CHF25.55B
2023 EBITDA Forecast
CHF26.50B
2024 EBITDA Forecast
CHF27.39B
2025 EBITDA Forecast
CHF28.47B
2026 EBITDA Forecast
CHF29.48B
2027 EBITDA Forecast
CHF30.51B
2028 EBITDA Forecast
CHF31.59B
2029 EBITDA Forecast
CHF32.66B
2030 EBITDA Forecast
CHF33.76B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
A Stock Forecast Agilent Technologies Outperform 7
$124.41 $172.40 28.61% 2
DD Stock Forecast DuPont de Nemours Outperform 3
$64.64 $98.25 36.14% 7
BIIB Stock Forecast Biogen Outperform 4
$202.54 $287.21 12.32% 24

Roche Holding EBIT Forecast for 2022 - 2025 - 2030

In the last three years, Roche Holding's EBIT has grown by 6.7%, rising from CHF18.92B to CHF20.19B. For next year, analysts predict earnings per share of CHF21.48B, which would mean an increase of 6.42%. Over the next nine years, experts predict that Roche Holding's EBIT will grow at a rate of 52.41%.

2022 EBIT Forecast
CHF21.48B
2023 EBIT Forecast
CHF22.57B
2024 EBIT Forecast
CHF23.57B
2025 EBIT Forecast
CHF24.76B
2026 EBIT Forecast
CHF25.90B
2027 EBIT Forecast
CHF27.07B
2028 EBIT Forecast
CHF28.28B
2029 EBIT Forecast
CHF29.51B
2030 EBIT Forecast
CHF30.77B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4503 Stock Forecast Astellas Pharma Outperform 2
¥1.80k ¥0.00 33.33% 0
DXCM Stock Forecast DexCom Buy 0
$288.13 $560.79 82.21% 3
CERN Stock Forecast Cerner Hold 6
$94.44 $93.31 0.59% 3

Roche Holding EPS Price Prediction Forecast for 2022 - 2025 - 2030

Roche Holding's EPS has increased by 9.21% in the last three years, going from CHF18.14 to CHF19.81. In the next year, analysts expect EPS to reach an unimpressive CHF21.03 – an increase of 6.17%. For the next nine years, the forecast is for EPS to grow by 51.11%.

2022 EPS Forecast
CHF21.03
2023 EPS Forecast
CHF22.04
2024 EPS Forecast
CHF23.04
2025 EPS Forecast
CHF24.17
2026 EPS Forecast
CHF25.26
2027 EPS Forecast
CHF26.39
2028 EPS Forecast
CHF27.55
2029 EPS Forecast
CHF28.73
2030 EPS Forecast
CHF29.93
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
FME Stock Forecast Fresenius Medical Care AG & Co... Hold 4
56.30€ 80.66€ 16% 11
CE Stock Forecast Celanese Outperform 7
$149.47 $190.67 26.45% 20
BIO Stock Forecast Bio-Rad Laboratories Outperform 7
$518.73 $701.33 34.94% 2

© Copyright 2022 | Stock Forecast | All Rights Reserved